Figure 4.
![Figure 4. Survival analyses of intermediate cytogenetic risk AML patients with and without FLT3 ITD and/or NPM1 mutations. Kaplan-Meier estimates of OS (panels A and B) and EFS (panels C and D) for patients with intermediate-risk AML and FLT3 ITD mutations (FLT3 ITD positive [panels B and D]) versus those with intermediate-risk AML without FLT3 ITD mutations (FLT3 ITD negative [panels A and C]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/106/12/10.1182_blood-2005-05-2168/2/zh80240587560004.jpeg?Expires=1735522134&Signature=5HsAh1nj7BjLTqkZpxaYGevN4bt-ITYXGayDxPrXw1~snfzz0xxVGCZCoXYl9etePLJH7T3tmoaY2MVvumMyfm2ijWC2alzrqCDl38SfQIoBl3yRoFOLNs3kGjtYebS5L3PuK-RV7I0E-bXxoF0lHmSK7zW69p~2dIuqT3~tqlUBFY6QcNoTzZcbWuCD7mvXa0k6KnUCJqv8e4WlGDvw5~32GuWz16IymFYDbNCRGft6-drMMVjsuQNQF0nLNbeZpOM~I2-2hzS3Uw08touLAaHoUJB2vbXiEG5ueUkhYZVd5oiSb3S1xmF1V-mWWRvnAg5Q~3sofoR6b0CAmi9qsw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival analyses of intermediate cytogenetic risk AML patients with and without FLT3 ITD and/or NPM1 mutations. Kaplan-Meier estimates of OS (panels A and B) and EFS (panels C and D) for patients with intermediate-risk AML and FLT3 ITD mutations (FLT3 ITD positive [panels B and D]) versus those with intermediate-risk AML without FLT3 ITD mutations (FLT3 ITD negative [panels A and C]).
